adverse reactions to ceftazidime were severe , and the drug was discontinued in 13 of 570 ( 2.3 percent ) patients with skin or skin structure infections and in five of 134 ( 3.7 percent ) patients with bone and joint infections .
C0262950
bone
C0157749
joint